The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Tangible benefit for FLT3-ITD R/R AML on quizartinib
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the characterization of response and transfusion independence in relapsed/refractory FLT3-ITD mutated acute myeloid leukemia (AML) patients treated with quizartinib or salvage chemotherapy on the QuANTUM-R trial (NCT02039726). This revealed a tangible benefit from quizartinib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
